Riskpilot← Back to searchSign inGet full accessUroMedical Stockholm AB
ABActiveOrg 5591183149Drottninggatan 97 3trMedical specialists activities · NACE 8622Est. 201724 employees
Revenue 2025
SEK 73,9M
+37% vs 2024
EBITDA margin
-6.4%
-26% vs 2024
Equity ratio
27.7%
Financial strength
Net profit 2025
SEK 0
+100% vs 2024
| Revenue | SEK 73,9M | +37% |
| EBITDA | SEK -4,7M | -26% |
| Net profit | SEK 0 | +100% |
| Total assets | SEK 27,6M | +62% |
| Equity | SEK 7,6M | +256% |
| Employees | 24 | — |
Legal name
UroMedical Stockholm AB
Org number
5591183149
Legal form
Aktiebolag
NACE code
8622 · Medical specialists activities
Founded
5 juli 2017
Share capital
SEK 200 000
Employees
24 (FTE)
VAT registered
No
Audit selected
No
Last report
2025-12-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen Firman tecknas i förening av ledamöterna suppleanten Dessutom har verkställande direktören rätt att teckna firman beträffande löpande förvaltningsåtgärder
Company purpose
Bolaget ska bedriva sjukvård med inriktning på urologi samt därmed förenlig verksamhet.
Address
Drottninggatan 97 3tr
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | 33 939 | 29 245 | 42 789 | 54 093 | 73 859 |
| Staff expenses | — | −12 082 | −15 154 | −21 406 | −28 978 |
| EBITDA | 3 843 | −6 643 | 1 229 | −3 740 | −4 731 |
| Depreciation & amort. | −1 558 | −1 607 | −525 | −688 | −1 514 |
| EBIT | 2 285 | −8 250 | 703 | −4 429 | −6 244 |
| Net financials | −2 | −88 | 16 | −11 850 | −423 |
| Profit before tax | 1 256 | 1 341 | 0 | −13 089 | 0 |
| Tax | −269 | −302 | — | — | — |
| Net profit | 987 | 1 038 | 0 | −13 089 | 0 |
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Total assets | 13 860 | 14 991 | 18 116 | 17 024 | 27 646 |
| Equity | 6 499 | 7 537 | 7 537 | 2 148 | 7 648 |
| Long-term debt | 0 | — | — | — | 546 |
| Short-term debt | 2 844 | 4 265 | 6 009 | 14 877 | 19 452 |
| Total debt | 2 844 | 4 265 | 6 009 | 14 877 | 19 999 |
EBITDA margin
-6.4%
This company
15.8%
Market median
-141% vs market
20212025
Equity ratio
27.7%
This company
38.2%
Market median
-27% vs market
20212025
Return on equity
0.0%
This company
18.4%
Market median
-100% vs market
20212025
Net profit margin
0.0%
This company
8.1%
Market median
-100% vs market
20212025
Asset turnover
2.67×
This company
1.12×
Market median
+138% vs market
20212025
Debt / equity
2.62×
This company
0.62×
Market median
-323% vs market
20212025
- Annual report 2025Filed via Bolagsverket / SCB · Period 2025-01-01 – 2025-12-31
- Annual report 2024Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2021-01-01 – 2021-12-31
| Name | Role | Member since |
|---|---|---|
| Current (3) | ||
ER Chief Executive Officer | Chief Executive Officer | 2026 |
KK Chief Auditor | Chief Auditor | 2022 |
AU Chief Executive Officer | Chief Executive Officer | 2022 |
| Former (4) | ||
TH Chief Executive Officer | Chief Executive Officer | 2023 – 2023 |
CM Chief Executive Officer | Chief Executive Officer | 2020 – 2022 |
MS Chief Auditor | Chief Auditor | 2020 – 2022 |
RG Chief Executive Officer | Chief Executive Officer | 2022 – 2022 |
| Name | Role | Member since |
|---|---|---|
| Current (2) | ||
| Deputy Board Member | 2024 | |
| Chairman | 2025 | |
| Former (7) | ||
| Chairman | 2020 – 2022 | |
| Board of Directors | 2022 – 2024 | |
| Chairman | 2024 – 2025 | |
| Board of Directors | 2020 – 2022 | |
| Chairman | 2023 – 2023 | |
| Board of Directors | 2022 – 2024 | |
| Chairman | 2020 – 2020 | |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
| Company | 100% | 100% | 2025 | |
| Company | 100% | 100% | 0001 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
ARMADA FUND V KY
UroMedical Stockholm AB Board members of UroMedical Stockholm AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Erik Rönnblad | Chief Executive Officer | 0 companies |
| Thomas Haugen Skorpen | Chief Executive Officer | 0 companies |
| Karin Kristina Eriksson | Chief Auditor | 0 companies |
| Carl Magnus Annerstedt | Chief Executive Officer | 0 companies |
| Mikael Sjölander | Chief Auditor | 0 companies |
| Robert Gelmanovski | Chief Executive Officer | 0 companies |
| Anna Ulrika Hansson | Chief Executive Officer | 0 companies |
| Hans Börje Persson | Chairman | 0 companies |
| Øyvind Bakke | Board of Directors | 0 companies |
| Fred Rosendal Helgesen | Chairman | 0 companies |
| Bo Daniel Rafael Lantz | Board of Directors | 0 companies |
| Patrik Bø Egeland | Chairman | 0 companies |
| Anna Maria Kristina Frånlund | Board of Directors | 0 companies |
| Jan-Olof Wiklund | Deputy Board Member | 0 companies |
| Daniel Robert Öhman | Chairman | 0 companies |
| Jonathan Kimber | Chairman | 0 companies |